BNOX

Bionomics Limited - American Depository Sh…

1.30 USD

Last updated Dec 10, 23:28 UTC

Yesterday HIGH

$1.33

Yesterday LOW

$1.24

52w HIGH

$7.71

52w LOW

$0.93

EPS

1

PE

1.30

Overview News Government Trades

Bionomics Limited - American Depository Sh… stock is down -25.29% since 30 days ago. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

Bionomics Limited discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trials for social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the. treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed. phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

bionomics.com.au

Lisa Levin

Thu Sep 28, 2023

Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Benzinga Newsdesk

Thu Sep 28, 2023

Maxim Group Maintains Buy on Bionomics, Raises Price Target to $10

Maxim Group analyst Jason McCarthy maintains Bionomics (NASDAQ:BNOX) with a Buy and raises the price target from $7 to $10.
Benzinga Newsdesk

Thu Sep 28, 2023

HC Wainwright & Co. Upgrades Bionomics to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Bionomics (NASDAQ:BNOX) from Neutral to Buy and announces $8 price target.
Lisa Levin

Thu Sep 28, 2023

Crude Oil Moves Lower; CarMax Posts Downbeat Earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining 1% on Thursday. The Dow traded up 0.58% to 33,745.23 while the NASDAQ rose 1% to 13,223.61. The S&P 500 also rose, gaining, 0.81% to 4,309.27.
Lisa Levin

Thu Sep 28, 2023

Dow Rises 80 Points; US Jobless Claims Edge Higher

U.S. stocks traded higher this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 33,630.52 while the NASDAQ rose 0.12% to 13,108.31. The S&P 500 also rose, gaining, 0.25% to 4,285.08.
Benzinga Insights

Thu Sep 28, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
ryanfaloona@benzinga.com

Thu Sep 28, 2023

Market-Moving News for September 28th

BNOX: 700% | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) PTON: 39% | Peloton shares are
Vandana Singh

Thu Sep 28, 2023

Why Is Stress Disorder Focused Bionomics Stock Trading Higher Today?

Bionomics Limited (NASDAQ: BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic
Benzinga Newsdesk

Thu Sep 28, 2023

Bionomics' Phase 2B Attune Trial Met Its Primary Endpoint Showing BNC210 Treatment Led To A Statistically Significant Reduction In Total PTSD Symptom Severity At 12 Weeks
Benzinga Insights

Tue Sep 19, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's session, 275 companies made new 52-week lows.